Agustín Melián, M.D. to be named Executive Vice
President, Head of Research and Development and Linea Aspesi to be
named Senior Vice President, Chief Human Resources Officer
Appointments position Forma for the next phase
of growth in late-stage global development and
commercialization
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a
clinical-stage biopharmaceutical company focused on sickle cell
disease, prostate cancer, and other rare hematologic diseases and
cancers, today announced the appointment of Agustín Melián, M.D. to
EVP, head of research and development and Linea Aspesi to SVP,
chief human resources officer. Both executives will join Forma
effective July 11, 2022.
“As the company continues to expand globally to prepare to
deliver transformative medicines to patients, we are very pleased
to welcome Agustín and Linea, as they bring extensive experience in
late-stage global drug development and commercialization,” said
Frank D. Lee, president and chief executive officer of Forma.
Agustín Melián, M.D.
With more than 20 years in industry, Dr. Melián has developed an
impressive track record developing patient-centric, rare and orphan
disease therapies across multiple therapeutic areas, multiple
modalities, and all phases of development. As the first chief
medical officer at AlloVir, Inc., Dr. Melian played a foundational
role building its development organization, taking the company
through its initial public offering, and advancing programs through
early and late-stage development. Dr. Melián also served as an SVP
at Alexion Pharmaceuticals, Inc., managing multiple therapeutic
areas and functions, while advancing programs that quadrupled the
number of products on the market during his tenure at the company.
Prior to Alexion, Dr. Melián served more than thirteen years at
Merck & Co, Inc. in various development roles of increasing
responsibility, including as global medical organization leader and
head of emerging markets clinical development, and head of Japanese
clinical development. In this capacity, he led the cross-functional
research and development medical staff outside of the U.S. as well
as Japan. He oversaw clinical trial execution in approximately 40
countries including in Latin America, Eastern Europe, the Middle
East, Africa, and Asia. Dr. Melián received his B.S. in molecular
biochemistry and biophysics along with an M.D. from Yale
University. He completed his post-graduate training at Brigham and
Women’s Hospital.
“As a physician-scientist with more than twenty years of
experience developing novel therapies, I am looking forward to
advancing the exciting portfolio at Forma, while improving the
lives of the patients it seeks to serve,” said Dr. Melián.
Linea Aspesi
Ms. Aspesi brings more than twenty-five years of human resources
leadership experience in life sciences and health care services to
Forma with proven success aligning talent plans to company vision,
mission, values, and strategy while fostering an equitable,
inclusive, and dynamic environment. As chief human resources
officer at Saniona, Inc., Ms. Aspesi partnered with the CEO to
build a diverse executive team and functions, in addition to
defining and driving cultural transformational strategies to
prepare the organization for commercial launch. At Sobi, Inc., she
served as vice president and head of human resources & office
management for North America where she provided strategic
leadership to design and execute a significant expansion strategy
of the North American business in sales/marketing, market access
and government affairs, medical affairs, and commercial innovation.
Prior to Sobi, she served as head of human resources and a member
of the North America HR leadership team at Sanofi, shaping talent
strategies for the North America manufacturing and quality
organization, Boston Hub Research and Development, and Sanofi
Genzyme.
“Forma has a differentiated patient-centric culture and an
amazing team. I’m excited to join and help further the diverse
culture and development of the organization and people as the
company continues its journey to deliver transformative medicines
to patients,” said Ms. Aspesi.
As Ms. Aspesi steps into her role, SVP, corporate affairs &
chief human resources officer Mary Wadlinger will step down and
serve as a consultant and advisor to assist with the transition.
Since 2014, Ms. Wadlinger has played a vital role in establishing
the culture at Forma and in evolving the organization from a
company focused on research to now late-stage development. She not
only built but also led our patient engagement, corporate
communications, and human resources functions. “We want to thank
Mary for her contributions in boldly advancing our purpose and for
caring deeply for our people and the patients we serve,” said Mr.
Lee.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company
focused on the research, development, and commercialization of
novel therapeutics to transform the lives of patients with rare
hematologic diseases and cancers. Our R&D engine combines deep
biology insight, chemistry expertise and clinical development
capabilities to create drug candidates with differentiated
mechanisms of action focused on indications with high unmet need.
Our work has generated a broad proprietary portfolio of programs
with the potential to provide profound patient benefit. For more
information, please visit www.FormaTherapeutics.com or follow us on
Twitter @FORMAInc and LinkedIn.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, express or implied
statements regarding the company’s beliefs and expectations
regarding its: business development, plans and objectives; expected
start date for employment of Dr. Melián and Ms. Aspesi; future
plans for development, including expectations regarding late-stage
global drug development and commercialization; and mechanisms of
action, benefits and safety of our product candidates. The words
“may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs and are subject to
a number of risks, uncertainties and important factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in
this press release, including, without limitation, those risks and
uncertainties associated with the following: the impact of the
COVID-19 pandemic on the company’s business, operations, supply
chain, patient enrollment and retention, clinical trials, strategy,
goals and anticipated milestones, as well as global economies and
financial markets; the therapeutic potential of our product
candidates and the timing and completion of our clinical trials and
related data analyses; positive results from a clinical study may
not necessarily be predictive of the results of future or ongoing
clinical studies; any one or more of our product candidates may not
be successfully developed and commercialized; regulatory
developments in the United States and foreign countries; our
ability to protect and maintain our intellectual property position;
and our ability to fund operations; as well as those risks and
uncertainties set forth more fully under the caption "Risk Factors"
in our most recent annual report on Form 10-Q filed with the United
States Securities and Exchange Commission (SEC) and subsequent
filings with the SEC. We disclaim any obligation to publicly update
or revise any such statements to reflect any change in expectations
or in events, conditions or circumstances on which any such
statements may be based, or that may affect the likelihood that
actual results will differ from those set forth in the
forward-looking statements. Any forward-looking statements
contained in this press release represent our views only as of the
date hereof and should not be relied upon as representing our views
as of any subsequent date.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220630005268/en/
Media: Johanna Bennett, +1-973-600-7925 Porter Novelli
johanna.bennett@porternovelli.com
Investors: Adam Bero, Ph.D. Kendall Investor Relations
abero@kendallir.com
Forma Therapeutics (NASDAQ:FMTX)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Forma Therapeutics (NASDAQ:FMTX)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
